Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without ...

Several companies rightfully used the heavily sought-after screen time to raise awareness and send powerful messages, and it ...

After a telehealth company's Super Bowl commercial sparked nationwide debate about pharmaceutical safety and advertising, one DSO executive is reflecting on what the controversy means for patient care ...

Hims & Hers has capitalized on the outsize consumer demand for obesity drugs. (Hims & Hers Health) Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug ...